EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Co-Administration Dosing of Ceftazidime–Avibactam and Aztreonam in Patients with Varying Renal Function for Carbapenem-Resistant Enterobacterales Infections via Monte Carlo Simulation

Jatapat Hemapanpairoa iD, Weerayuth Saelim iD, Dhitiwat Changpradub iD, Wichai Santimaleeworagun iD

Infection & Chemotherapy · 2026 · 58 (1) · 82

DOI: 10.3947/ic.2025.0132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection & Chemotherapy, 2026. Verfasst von Jatapat Hemapanpairoa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For infections caused by metallo-β-lactamase (MBL)-producing carbapenem-resistant Enterobacterales (CRE), ceftazidime-avibactam (CZA) alone is inactive because avibactam does not inhibit MBLs. Co-administration with aztreonam can restore activity but requires simultaneous delivery and harmonization of non-aligned renal dose adjustments. Pharmacodynamic (PD) targets for MBL producers may also differ from those for serine β-lactamase producers. This study aimed to define practical CZA plus aztreonam dosing regimens across renal function strata using Monte Carlo simulation. MATERIALS AND METHODS: >80 mg/L was applied as a neurotoxicity risk threshold. RESULTS: >80 mg/L) remained low across renal strata. CONCLUSION: Co-administration of CZA and aztreonam using renal-adjusted doses provides a practical and effective strategy for MBL-CRE infections. This approach ensures high joint PTA attainment while maintaining a low neurotoxicity risk across all renal function strata.

Schlagwörter

Stichwörter der Autor:innen

AztreonamCarbapenem-resistant EnterobacteralesCeftazidime-avibactamMetallo-β-lactamaseMonte Carlo simulation

Autor:innen und Institutionen

  • Division of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand.
  • Division of Infectious Disease, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
  • Pharmaceutical Initiative for Resistant Bacteria and Infectious Diseases Working Group [PIRBIG], Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand. swichai1234@gmail.com.

ORCID-Profile: Jatapat Hemapanpairoa, Weerayuth Saelim, Dhitiwat Changpradub, Wichai Santimaleeworagun

Zitieren

APA

Hemapanpairoa, J., Saelim, W., Changpradub, D., & Santimaleeworagun, W. (2026). Co-Administration Dosing of Ceftazidime–Avibactam and Aztreonam in Patients with Varying Renal Function for Carbapenem-Resistant Enterobacterales Infections via Monte Carlo Simulation. Infection & Chemotherapy, 58(1), 82. https://doi.org/10.3947/ic.2025.0132

Vancouver

Hemapanpairoa J, Saelim W, Changpradub D, Santimaleeworagun W. Co-Administration Dosing of Ceftazidime–Avibactam and Aztreonam in Patients with Varying Renal Function for Carbapenem-Resistant Enterobacterales Infections via Monte Carlo Simulation. Infection & Chemotherapy. 2026;58(1):82. doi:10.3947/ic.2025.0132

BibTeX
@article{Hemapanpairoa2026,
  author = {Hemapanpairoa, Jatapat and Saelim, Weerayuth and Changpradub, Dhitiwat and Santimaleeworagun, Wichai},
  title = {Co-Administration Dosing of Ceftazidime–Avibactam and Aztreonam in Patients with Varying Renal Function for Carbapenem-Resistant Enterobacterales Infections via Monte Carlo Simulation},
  journal = {Infection & Chemotherapy},
  year = {2026},
  volume = {58},
  number = {1},
  pages = {82},
  doi = {10.3947/ic.2025.0132}
}
Kostenlos starten →